Merrimack was the Cambridge biotech behind liposomal irinotecan (Onivyde), approved for pancreatic cancer in 2015 and later sold to Ipsen; its antibody programmes failed and the company wound down.
Merrimack Pharmaceuticals, founded in 2000 in Cambridge, Massachusetts, developed MM-398, a liposomal formulation of irinotecan approved in 2015 as Onivyde for metastatic pancreatic cancer after gemcitabine (the NAPOLI-1 trial), which it sold to Ipsen in 2017. Its systems-biology antibody programmes, including the HER3 antibody seribantumab, did not reach approval, and the company later returned remaining assets to shareholders. Its phase 3 trials remain on ClinicalTrials.gov under Merrimack as lead sponsor.
Irinotecan is a topoisomerase-blocking chemotherapy central to bowel and pancreatic cancer regimens (FOLFIRI, FOLFIRINOX, NALIRIFOX) and to salvage therapy in childhood sarcomas; it carries the same warhead as the deruxtecan ADC payloads.
Shares Pivotal (registrational) trial, Clinical trial, Pancreatic ductal adenocarcinoma.
Shares Pivotal (registrational) trial, Clinical trial, Pancreatic ductal adenocarcinoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/